The National Cancer Research Institute (NCRI)

New link between growth factors and early prostate cancer found

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease. A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

6 November 2010

Ten minute talk boosts breast cancer awareness six fold

A ten minute talk between a woman and a health professional increases the chances she will be 'breast cancer aware' by six fold, according to research published online in the British Journal of Cancer (BJC) and presented at the NCRI Cancer Conference in Birmingham. A ten minute talk between a woman and a health professional increases the chances she will be 'breast cancer aware' by six fold, according to research published online in the British Journal of Cancer (BJC) and presented at the NCRI Cancer Conference in Birmingham.

8 October 2009

• Health & Medicine

Manchester scientists take on cancer with pioneering radiotherapy treatment

Manchester scientists are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday). Manchester scientists are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

8 October 2009

Targeted breast cancer messages for ethnic minority women urgently needed

Black and Asian women are significantly more likely than white women to be diagnosed with breast cancer that has spread, reveals research presented at the NCRI Cancer Conference in Birmingham. Black and Asian women are significantly more likely than white women to be diagnosed with breast cancer that has spread, reveals research presented at the NCRI Cancer Conference in Birmingham.

7 October 2009

• Health & Medicine

Knowledge boosts pain killing drugs

Giving cancer patients information on how to deal with their pain and manage their medicine can result in a 20 per cent improvement in pain control, according to research presented at the NCRI Cancer Conference in Birmingham. Giving cancer patients information on how to deal with their pain and manage their medicine can result in a 20 per cent improvement in pain control, according to research presented at the NCRI Cancer Conference in Birmingham.

7 October 2009

Polite Britons risk late cancer diagnosis

Almost forty per cent of British people would put off going to their GP with cancer symptoms because they don't want to bother the doctor, reveals a survey published online in the British Journal of Cancer (BJC) and presented at the NCRI Cancer Conference in Birmingham. Almost forty per cent of British people would put off going to their GP with cancer symptoms because they don't want to bother the doctor, reveals a survey published online in the British Journal of Cancer (BJC) and presented at the NCRI Cancer Conference in Birmingham.

7 October 2009

• Science & Technology

Discovery offers hope for new cancer treatments

SCIENTISTS have discovered why a group of cancer drugs are so effective in treating the disease. Although they have been used for many years to treat certain tumours, researchers didn't know how they worked until now. SCIENTISTS have discovered why a group of cancer drugs are so effective in treating the disease. Although they have been used for many years to treat certain tumours, researchers didn't know how they worked until now.

6 October 2009

• Health & Medicine

Landmark breast cancer trial investigates new technique to predict effectiveness of treatment

The largest clinical trial of its kind - which aims to find out if testing breast cancer cells after two weeks of hormone therapy can help predict how well a woman will respond to treatment - is being outlined at the NCRI Cancer Conference. The largest clinical trial of its kind - which aims to find out if testing breast cancer cells after two weeks of hormone therapy can help predict how well a woman will respond to treatment - is being outlined at the NCRI Cancer Conference.

6 October 2009

• Health & Medicine

Experimental drug may work in many cancers

Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today.

6 October 2009

• Health & Medicine

Cardiff scientists take on leukaemia with drugs personalised to individual patients

Cardiff scientists are treating leukaemia by trialling new drugs tailored to individual patientsї genetic make-up. Cardiff scientists are treating leukaemia by trialling new drugs tailored to individual patientsї genetic make-up.

6 October 2009

Wandering breast cancer cells can stay dormant for decades

A provocative new theory that breast cancer cells can self-seed by wandering off round the body and returning to the primary tumour, or can stay in the body for several decades after the disease appeared to be cured before growing or seeding in other organs, could pave the way for new therapies to destroy these wandering cells that have escaped initial treatment. A provocative new theory that breast cancer cells can self-seed by wandering off round the body and returning to the primary tumour, or can stay in the body for several decades after the disease appeared to be cured before growing or seeding in other organs, could pave the way for new therapies to destroy these wandering cells that have escaped initial treatment.

5 October 2009

Cancer Research UK and AstraZeneca to accelerate biomarker research

AstraZeneca is to double its investment in Cancer Research UKїs biomarker research in an effort to better understand how drugs behave in early stage clinical trials. AstraZeneca is to double its investment in Cancer Research UKїs biomarker research in an effort to better understand how drugs behave in early stage clinical trials.

5 October 2009